Compare Gilead Sciences, Inc. (GILD) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Realty Income Corp — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Realty Income Corp trades at $54.25 (market cap $51.26B). The key difference: Gilead Sciences, Inc. is far larger — about 3.6× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Realty Income Corp for 127 Days on average.
| GILD | O | |
|---|---|---|
Market Cap | $182.40B | $51.26B |
Volume | 4,469,821 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $155.80 | $67.56 |
52-Week Low | $116.74 | $53.35 |
Typical Hold Time | 111 Days | 127 Days |
Enterprise Value | $205.46B | $81.88B |
Dividend Yield | 2.23% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Realty Income (O) trades at $53.35, down 1.66% amid a bearish technical signal, with support at $52. The stock has missed EPS estimates for three consecutive quarters but maintains a 92.56% gross margin and 21.23% net income margin. Recent news highlights its 6% dividend yield and 136 consecutive dividend increases, though rising Treasury yields pressure REIT valuations.
The outlook is mixed: analyst consensus targets $64.80 (21% upside) with a 'Hold' bias, but debt-to-asset ratios have risen to 39.93% (2025). Key risks include interest rate sensitivity and earnings misses, while the dividend track record offers income stability. Investors face trade-offs between yield sustainability and fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
